Pathway candidateNCBI-verifiedprotein-coding

SLCO2A1

solute carrier organic anion transporter family member 2A1

NCBI Gene: 6578 Ensembl GeneCards UniProt: Q92959

Pathway candidate — not linked to PFS or PSSD by any record here

SLCO2A1 is in the library because it belongs to the drug transporters family. No study, report or commentary in the corpus names it, so a variant in SLCO2A1 is not, by itself, evidence of anything related to post-drug syndromes.

Gene summary

A protein-coding gene on chromosome 3 (drug and xenobiotic transporters). Encodes a prostaglandin transporter that is a member of the 12-membrane-spanning superfamily of transporters. The protein may be involved in mediating the uptake and clearance of prostaglandins in numerous tissues.

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Solute carrier organic anion transporter family member 2A1
Function (excerpt): Mediates the transport of prostaglandins (PGs, mainly PGE2, PGE1, PGE3, PGF2alpha, PGD2, PGH2) and thromboxanes (thromboxane B2) across the cell membrane. PGs and thromboxanes play fundamental roles in diverse functions such as intraocular pressure, gastric acid secretion, renal salt and water transport, vascular tone, and fever. Plays a role in the clearance of PGs from the circulation through cellular uptake, which allows cytoplasmic oxidation and PG signal termination. PG uptake is dependent upon membrane potential and involves exchange of a monovalent anionic substrate (PGs exist physiologically as an anionic monovalent form) with a stoichiometry of 1:1 for divalent anions or of 1:2 for monovalent anions. Uses lactate, generated by glycolysis, as a counter-substrate to mediate PGE2 influx and efflux. Under nonglycolytic conditions, metabolites other than lactate might serve as counter-substrates.
Subcellular location: Cell membrane; Basal cell membrane; Cytoplasm; Lysosome.
Tissue specificity: Ubiquitous. Significant expression observed in lung, kidney, spleen, and heart. Expressed in the endometrium (at both mRNA and protein levels). Expressed in the ovaries (at mRNA and protein levels). In testis, primarily localized to the basal membrane of Sertoli cells and weakly expressed within the tubules.
Associated conditions: PHOAR2-enteropathy syndrome (PHOAR2E); Hypertrophic osteoarthropathy, primary, autosomal dominant (PHOAD).

Source: UniProtKB/Swiss-Prot Q92959, release 2026_03, licensed CC BY 4.0. This is the protein’s normal biology, not evidence about post-drug syndromes; associated conditions are inherited disorders of the gene, not PFS, PSSD or PRSD.

Why its pathway is in the library

Transporters set systemic exposure to finasteride/SSRIs and clear conjugated steroid metabolites — directly relevant to both drug pharmacokinetics and Powers' clearance-centered PFS mechanism.

Written for the whole drug transporters family, not for SLCO2A1 specifically.

Mentioned in 0 corpus records

No corpus record names SLCO2A1 directly yet. It is in the library because it sits in a pathway the corpus tracks (Drug transporters).

Also in drug and xenobiotic transporters

All 62 genes

Browse by family on the gene families page.

Gene summary

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Solute carrier organic anion transporter family member 2A1
Function (excerpt): Mediates the transport of prostaglandins (PGs, mainly PGE2, PGE1, PGE3, PGF2alpha, PGD2, PGH2) and thromboxanes (thromboxane B2) across the cell membrane. PGs and thromboxanes play fundamental roles in diverse functions such as intraocular pressure, gastric acid secretion, renal salt and water transport, vascular tone, and fever. Plays a role in the clearance of PGs from the circulation through cellular uptake, which allows cytoplasmic oxidation and PG signal termination. PG uptake is dependent upon membrane potential and involves exchange of a monovalent anionic substrate (PGs exist physiologically as an anionic monovalent form) with a stoichiometry of 1:1 for divalent anions or of 1:2 for monovalent anions. Uses lactate, generated by glycolysis, as a counter-substrate to mediate PGE2 influx and efflux. Under nonglycolytic conditions, metabolites other than lactate might serve as counter-substrates.
Subcellular location: Cell membrane; Basal cell membrane; Cytoplasm; Lysosome.
Tissue specificity: Ubiquitous. Significant expression observed in lung, kidney, spleen, and heart. Expressed in the endometrium (at both mRNA and protein levels). Expressed in the ovaries (at mRNA and protein levels). In testis, primarily localized to the basal membrane of Sertoli cells and weakly expressed within the tubules.
Associated conditions: PHOAR2-enteropathy syndrome (PHOAR2E); Hypertrophic osteoarthropathy, primary, autosomal dominant (PHOAD).